Cargando…

Anti-c-myc RNAi-Based Onconanotherapeutics

Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Habib, Saffiya, Ariatti, Mario, Singh, Moganavelli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765184/
https://www.ncbi.nlm.nih.gov/pubmed/33333729
http://dx.doi.org/10.3390/biomedicines8120612
_version_ 1783628432193617920
author Habib, Saffiya
Ariatti, Mario
Singh, Moganavelli
author_facet Habib, Saffiya
Ariatti, Mario
Singh, Moganavelli
author_sort Habib, Saffiya
collection PubMed
description Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020.
format Online
Article
Text
id pubmed-7765184
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77651842020-12-27 Anti-c-myc RNAi-Based Onconanotherapeutics Habib, Saffiya Ariatti, Mario Singh, Moganavelli Biomedicines Review Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020. MDPI 2020-12-15 /pmc/articles/PMC7765184/ /pubmed/33333729 http://dx.doi.org/10.3390/biomedicines8120612 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Habib, Saffiya
Ariatti, Mario
Singh, Moganavelli
Anti-c-myc RNAi-Based Onconanotherapeutics
title Anti-c-myc RNAi-Based Onconanotherapeutics
title_full Anti-c-myc RNAi-Based Onconanotherapeutics
title_fullStr Anti-c-myc RNAi-Based Onconanotherapeutics
title_full_unstemmed Anti-c-myc RNAi-Based Onconanotherapeutics
title_short Anti-c-myc RNAi-Based Onconanotherapeutics
title_sort anti-c-myc rnai-based onconanotherapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765184/
https://www.ncbi.nlm.nih.gov/pubmed/33333729
http://dx.doi.org/10.3390/biomedicines8120612
work_keys_str_mv AT habibsaffiya anticmycrnaibasedonconanotherapeutics
AT ariattimario anticmycrnaibasedonconanotherapeutics
AT singhmoganavelli anticmycrnaibasedonconanotherapeutics